GAMMA Investing LLC Buys 105 Shares of Illumina, Inc. (NASDAQ:ILMN)

GAMMA Investing LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,258 shares of the life sciences company’s stock after purchasing an additional 105 shares during the period. GAMMA Investing LLC’s holdings in Illumina were worth $310,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Illumina by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 18,178,513 shares of the life sciences company’s stock valued at $2,531,176,000 after acquiring an additional 210,755 shares during the last quarter. Edgewood Management LLC lifted its stake in shares of Illumina by 4.6% in the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock worth $957,762,000 after purchasing an additional 302,222 shares during the period. Capital World Investors purchased a new position in shares of Illumina in the fourth quarter worth approximately $271,753,000. Norges Bank bought a new stake in Illumina during the fourth quarter valued at approximately $264,636,000. Finally, Charles Schwab Investment Management Inc. grew its position in Illumina by 4.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 925,198 shares of the life sciences company’s stock valued at $128,825,000 after buying an additional 41,298 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 0.9 %

Shares of NASDAQ:ILMN opened at $108.10 on Thursday. The company has a market cap of $17.22 billion, a price-to-earnings ratio of -13.26 and a beta of 1.20. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $203.19. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $113.53 and a 200 day moving average price of $127.68.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 earnings per share. As a group, equities research analysts predict that Illumina, Inc. will post 1.04 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. Barclays lifted their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Illumina in a report on Tuesday, May 7th. Robert W. Baird raised their price objective on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Finally, StockNews.com assumed coverage on shares of Illumina in a report on Friday, June 14th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $158.14.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.